pubmed-article:3006358 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:3006358 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
pubmed-article:3006358 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:3006358 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
pubmed-article:3006358 | lifeskim:mentions | umls-concept:C0443286 | lld:lifeskim |
pubmed-article:3006358 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
pubmed-article:3006358 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:3006358 | pubmed:dateCreated | 1986-3-31 | lld:pubmed |
pubmed-article:3006358 | pubmed:abstractText | The capacity of leukocytes from children with primary immunodeficiency to produce alpha- and gamma-interferons in vitro was studied. Interferon response of leukocytes in most of the patients examined was found to be practically unchanged. The immunostimulating therapy in some cases exerted a regulating effect on leukocyte capacity for interferon production. It is assumed that the interferon-producing function of T lymphocytes may be preserved in patients suffering from primary immunodeficiency. | lld:pubmed |
pubmed-article:3006358 | pubmed:language | rus | lld:pubmed |
pubmed-article:3006358 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3006358 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:3006358 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3006358 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3006358 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:3006358 | pubmed:issn | 0507-4088 | lld:pubmed |
pubmed-article:3006358 | pubmed:author | pubmed-author:BabaiantsA... | lld:pubmed |
pubmed-article:3006358 | pubmed:author | pubmed-author:ManakhovaL... | lld:pubmed |
pubmed-article:3006358 | pubmed:author | pubmed-author:KarganovaG... | lld:pubmed |
pubmed-article:3006358 | pubmed:author | pubmed-author:Porkhovaty?S... | lld:pubmed |
pubmed-article:3006358 | pubmed:author | pubmed-author:KondratenkoI... | lld:pubmed |
pubmed-article:3006358 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:3006358 | pubmed:volume | 30 | lld:pubmed |
pubmed-article:3006358 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:3006358 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:3006358 | pubmed:pagination | 714-7 | lld:pubmed |
pubmed-article:3006358 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:meshHeading | pubmed-meshheading:3006358-... | lld:pubmed |
pubmed-article:3006358 | pubmed:articleTitle | [Leukocyte interferon reaction in patients with primary immunodeficiencies]. | lld:pubmed |
pubmed-article:3006358 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:3006358 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:3006358 | pubmed:publicationType | English Abstract | lld:pubmed |